

TUMOUR	TRIAL/AGENT: PHASE 1	KEY POINTS	PI	SC
Solid Tumour	AK104-101	Ph1A dose esc of AK104-101 (bispecific PD1 and CTLA4 inhibitor) for advanced solid. No prior IO.	BM	CAH
Solid Tumour	ARX788	Her2+ gastric/breast only. Failed std therapy. Prior HER2 directed therapy accepted. Local HER2 testing accepted.	BM	IN
Solid Tumour	BGB 900-101	BGB 333 (PDL1) + Tislelizumab for advanced solid tumours. Resistant std therapy. No prior IO.	BM	CAH
Solid Tumour	C-Stone Anti PDI	CS1003 (anti-PD1) in advanced solid tumor. Failed std therapy. No prior IO.	BM	JK
Solid Tumour	KX-ORAX-002	Bioequivalence study of paclitaxel (PO vs IV).	ES	IN
Solid Tumour	MedImmune (D6840C00001)	MEDI5083 (anti PD-L1) +/- Durvalumab. Selected solid tumors. Failed std therapy.	SF	PM
Solid Tumour	BMS IDO: inhib + nivolumab	BMS-986205 (IDO-inhibitor) + Nivo vs. BMS-986205 +Nivo/Ipi. Second line. Prior IO permitted in some cohorts.	BM	IN
Solid Tumour	Corvus: Adenosine antag +/- PDL1 (atezolizumab)	CPI-444 (adenosine2, receptor inhib.) +/- Atezolizumab. 2 nd line. No denosumab permitted in atezo arm. Tumors: NSCLC, MEL, RCC, TNBC, mCRPC, CRC (MSI-H), Bladder (urothelial).	BM	JK
Solid Tumour	BGB-900-103 (NSCLC, RCC and Ovarian specific to Anti-PD1/Pd-L1 status)	A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors	BM	CA
Liver Mets	T-Vec-20140299	mCRC/mTNBC (liver mets). Intrahepatic talvoglutin (oncolytic virus) + atezo (PD-L1). Failed 1L therapy. No prior loco-reg therapy to liver, no portal vein involvement. No prior IO.	BM	CAH
Oesophageal & GOJ	APROC: APR246 plus 5FU/cisplatin	APR-246 (p53 target) with cisplatin+ 5-FU in advanced or metastatic OES/GOJ (adeno or sq), platinum resistant, 3L prior (inc. adj), 2L prior in met setting.	BM	CB
Prostate	GSK525762 + abiraterone or enzalutamide mCRPC daily oral	GSK525762 (BET inhibitor) + ADT safety in mCRPC or CRPC adeno; 2 nd line. Prior taxane chemo allowed.	AA	CB
Ovarian/TNBC	BGB-A317 / 290:PD1 inh plus PARP inh	BGB-A317 (PD-1) plus BGB-290 (PARPi). Ovarian/TNBC, BRCAmut or HRD. Must have failed 2L platinum-based chemo.	BM	PM

Ph I
 Gastrointestinal (GI)
 Breast & Gynaecology
 Ovarian
 Head & Neck
 Lung
 Rare Cancers
 Genitourinary (GU)
 Other

STREAM CONTACT NUMBERS

Phase I	Gastrointestinal (GI)	Breast & Gynaecology	Lung and Other	Genitourinary (GU)
0474 769 510	0436 386 758	0491 299 561	0436 387 306	0436 387 664

TUMOUR	TRIAL	TRIAL/AGENT: PHASE 2/3	PI	SC
Breast	Contessa	Ph III, Teseaxel (taxane) + dose reduced Capecitabine vs Capecitabine. 2 nd line. HER-2 neg, ER/PR+, LA/MBC. 1L prior taxane in met; prior anthracycline/hormone where applicable.	MW	LC
Breast	AZTEC: Breast TNBC	Phase II comparing single fraction or multi-fraction SABR with Atezolizumab for advanced TNBC, Note: mandatory biopsies pre C1, C3 and progression, frequent imaging	MW	KB
Breast – Her2+	PATINA	Phase III palbociclib + std therapy vs. std therapy in ER/PR+, Her2+ MBC, 2 nd line	MW	LC
Ovarian	DYNAMIC	ctDNA as marker of disease in stage I-IV EOC. Post debulking. Exclude: mucinous, sarcoma types.	GG	KB
NSCLC	BR.31	Ph III, adjuvant MEDI4736 (PD-L1) vs placebo, resected stage IB/II/IIIA NSCLC, prior adj chemo permitted	PB	LM
NSCLC	OSCILLATE	Ph II trial, 2 nd line EGFR-TKI, alternating osimertinib with gefitinib in patients with EGFR-T790M +ve advanced NSCLC	PB	LT
Solid Tumour	KX-ORAX-003	Ph II, A Safety Study of Oraxol (HM30181 + oral paclitaxel) in Cancer Patients		
PEARL	PEARL	Early referral to pall care in lung cancer. Randomised. Ph III.	PP/MF	JH
Rare Cancers	Rare Cancers	Ph II, Ipi + Nivo for in Rare (UGI, NEC, Gynae). Prior single agent IO permitted.	BM	LM
Bladder TCC	Javelin Bladder	Avelumab +BSC vs BSC in maintenance 1 st line, LA/Met Urothelial TCC	DP	LG
Bladder TCC	FORT-1	A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum containing chemotherapy	DP	LG
Prostate	Unison	Phase 2, Sequential Trial of SA Nivo, then Combo Ipi + Nivo in Met or Unresectable RCC (non clear cell). 1 st L/2 nd L, no prior IO.	DP	LD
Prostate	MDV3800-06 MCRPC	Ph II, Talazoparib in MCRPC (DNA def mut), previous 1stL chemo, and progressed on abi/enza	EK	LD
Prostate	TheraP	Randomised, phase 2 trial of Lu-PSMA617 radionuclide vs cabazitaxel as 2 nd line MCRPC	EK	LG
Prostate	ICE-PAC	Ph II, Avelumab + SABR for MCRPC (adeno) up to 3 rd line	EK	LG
Prostate	EH prostate biology	Studies of prostate cancer biology	EK	NN
Renal	Fraction renal	Ph II, Ad/Met RCC (clear cell), Real time Ax of Nivo + combo, prior IO permitted, 2 nd line	DP	SK
Renal	Checkmate 9KD	Ph 2, Nivo plus (Rucaparid+Docetaxel OR Enza), MCRPC with 1 st line ADT	EK	SK
Renal	Keypad	Ph II, 2 nd line, Denosumab + Pembrolizumab in ccRCC	DP	SK
OES/GOJ	Checkmate G/O	Ph III, 1 st line Adjuvant Nivo vs placebo in resected OES/GOJ Stage II/III carcinoma with residual pathologic disease	AS	CP
OES/GOJ	INTEGRATE II	Ph III, Regorafenib vs placebo, in 2 nd L/3 rd L in met/locally recurrent GOJ/Stomach (adeno or undiff)	AS	CB
Gastric	BGB-290-303	Ph III, BGB-290 versus Placebo, maintenance in LA/Met Gastric adeno (HER2 neg), PR on prior IL platinum chemo	AS	CB
Gastric	TEND to upper GI cancer	RCT Telephone v Electronic Nutrition care to upper GI cancer patients and impact on QOL.	TH	LH
Gastric or GEJ	Keynote 811	Phase II 1st line treatment Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma	ES	CB
Gastric or GEJ	Spotlight	Phase III 1st line treatment for Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or GEJ Adenocarcinoma IMAB362 + FOLFOX6 v's Placebo + FOLFOX6	AS	SF
GIST	Blu-285-1303	Ph III, BLU-285 vs Regorafenib in LA/Met GIST	ES	MZ
Neuroendocrine	NABNEC	Ph II: G3 NEC, 1 st line carboplatin plus nab-paclitaxel	BM	CB
Pancreas	ASPEN	Asymp/non-func, pNET ≤ 2 cm, prospective evaluation	ES	MK
Pancreas	Dan Croagh	Panitumumab as 2 nd line for advanced PDAC (RASwt)	MH	SF
Pancreas	Medimmune D6070	Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma	SF	JK
Colorectal	Liberate	Liquid biopsy to determine RAS status in treatment naive mCRC	ES	CP
Colorectal	Monarcc	Ph II, Panitumumab vs panitumumab + 5-FU, as 1st line therapy, mCRC (RASwt/BRAFwt)	ES	SF
Colorectal	Dynamic	ctDNA to inform adjuvant chemo for stage II CRC	MH	CP
Colorectal	ASCOLT	Ph III, Adjuvant Aspirin vs placebo in secondary prevention CRC (Dukes C or high risk Dukes B)	AS	MZ
Rectal	AveRec	Neoadjuvant Avelumab + std therapy, locally advanced rectal	ES	MZ
Oncofertility	FUTuRE FERTILITY	Aged 45yrs or less, registry of pts who proceed or do not proceed for fertility management in newly diagnosed ca(all)	ES	AD